Roche Holding AG (RHHBY)
| Market Cap | 354.71B +35.4% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 23.22 |
| Forward PE | 16.95 |
| Dividend | 0.97 (1.67%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 1,070,581 |
| Open | 55.88 |
| Previous Close | 56.39 |
| Day's Range | 55.08 - 55.89 |
| 52-Week Range | 39.50 - 60.85 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 59.66 (+8.1%) |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $59.66, which is an increase of 8.10% from the latest price.
News
mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley
After BioNTech (BNTX) announced the discontinuation of its Phase 2 study partnered with Roche (RHHBY) of autogene cevumeran, an individualized mRNA immunotherapy, or cancer vaccine, in adjuvant colore...
Roche announces new two-year data from Phase IIIb/IV SALWEEN study
Roche (RHHBY) announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo, presented at the 19th Asia-Pacific Vitreo-retina Society Congress in Australia. The results showed significan...
Roche receives FDA approval for companion diagnostic tests for Ziihera
Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. “These companion diagnostics are now…
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis...
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday m...
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.
Labcorp to offer Elecsys pTau-217 test for Alzheimer’s disease
Labcorp (LH) announced it will offer the Elecsys pTau-217 test following clearance by the U.S. FDA. Developed by Roche Diagnostics (RHHBY), the blood test aids in identifying amyloid pathology associa...
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
INDIANAPOLIS, Aug. 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau...
Roche's US subsidiary Genentech announces manufacturing expansion in the United States
Basel, 20 August 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY) today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facilit...
Roche’s Genentech announces $750M manufacturing expansion in Hillsboro, GA
Genentech, a member of the Roche (RHHBY) Group, announced plans to invest approximately $750M in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investm...
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today announced plans to invest approximately $750 million in a new device...
Ideaya Biosciences enters IDE892 collaboration with Genentech
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Genentech, a member of Roche (RHHBY), to evaluate the efficacy and safety of IDE892, its investigational MTA-coope...
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Spr...
Drugmakers curb Swiss reimbursement applications over US pricing concerns
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by ...
Roche upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Roche (RHHBY) to Overweight from Equal Weight with a price target of $63, up from $46. The firm says the company offers a “strong mix of visible…
Roche launches two new cyclospora tests as US outbreak widens
Roche said on Thursday it launched two new tests to detect cyclospora, as U.S. cyclosporiasis cases climbed to record levels this year making the foodborne-illness outbreak one of the largest in the...
Roche expands cyclospora testing portfolio to support U.S. public health response
Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories. The new tests expand the Roche cyclospora portfolio, pro...
Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer
Labcorp (LH) announced the nationwide availability of Roche’s (RHHBY) VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. FDA to determine PT...
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, ...
Genprex announces collaboration with Roche Diagnostics
Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclini...
Roche announces EMA’s CHMP recommended approval of Susvimo
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Susvimo 100 mg/mL for the treatment of neovascu...
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginit...
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv...
Roche Holding AG Earnings Call Transcript: H1 2026
Core operating profit rose 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Pipeline momentum remains high with five FDA priority reviews and major launches in diagnostics and obesity. Currency headwinds and China reforms continue to impact results.